G liclazide belongs to a new group of second-generation hypoglycemic drugs, thiourea derivatives, used in medicine in the form of oral drugs having various degrees of active-substance release. In contrast with the first-generation drugs, the gliclazide preparations are of very high efficiency, so treatment doses are several times lower.
The nature of these drugs explains why it is necessary to seek new, sensitive, and accurate analytical methods (1) .
Many methods for the determination of gliclazide in pharmaceuticals are described in the literature. An important group consists of UV and visible spectrophotometric methods used after a colored derivative is obtained (2) (3) (4) (5) . Chromatographic methods using mainly liquid chromatography (LC; 6-8), thin-layer chromatography (TLC) often in combination with densitometry (9, 10), and gas chromatography (GC) with flame ionization detection (FID) and packed columns (in particular OV-1, OV-17, and XE-60; 11, 12) were also proven to be useful. In addition, electrochemical techniques such as voltammetry (13) and coulometry (14) have been developed for the determination of gliclazide in pharmaceuticals. According to the British Pharmacopoeia (15) , LC is recommended for assessment of gliclazide purity (15) .
The aim of this study was to develop a method for the identification and determination of gliclazide in oral drugs of various origins that are widely used in medicine, while taking into account the effect of the matrix on the results.
Experimental
Apparatus (a) GC system.-TRACE GC 2000 Series gas chromatograph (CE Instruments Thermo Quest, Rodano, Italy), equipped with a flame ionization detector (3 pg C/s, linearity 10 6 ) and 2 injectors: split-splitless and cold on-column. Injection port: cool on-column (cold on-column), secondary cooling time of 0.1 min. Temperature program for the GC oven: from 75°C (hold for 5 min) to 240°C at 10°C/min (hold for 18 min). Flame ionization detector: base body temperature, 275°C; air (350 mL/min); hydrogen (35 mL/min); and nitrogen (make-up gas, 30 mL/min).
( 
Preparation of Sample Solutions
Ten tablets, each containing 80 mg gliclazide declared, were ground, and amounts equivalent to the averaged mass of 1 tablet were weighed with an accuracy of ±0.1 mg; 25.0 mL methanol was added to each amount, and the mixtures were shaken for 15 min. The suspensions obtained were filtered through filter paper with medium-wide pores (No. 389, 9 cm diameter; FILTRAK ® , Niederschlag, Germany). For the internal standard method, at this point in the procedure 10.0 mL volumetric flasks each containing 500 µL internal standard solution were diluted to volume with appropriate filtrate.
Pharmaceutical Preparations Analyzed
The following randomly selected gliclazide preparations, available in the marketplace, originated from various manufacturers: (B)-(H) as in Figure 2 
Preliminary GC Analyses and Results
During preliminary investigations performed by 2 independent analysts, the conditions for the chromatographic separation of gliclazide were checked, and preliminary validation parameters were determined to establish the optimum conditions of analysis (16) .
Effect of parameter changes on the measurement of results.-The solutions of standard and pharmaceutical preparations for chromatography were fed into the chromatographic column at a constant flow rate (1.0-2.0 mL/min, 26-43 cm/s) or at a constant pressure (70-120 kPa) of carrier gas within different ranges of detector sensitivity, isothermally or with the temperature program for the GC oven in the range of 40-275°C, while the rate of temperature increase changed from 5 to 20°C/min and the duration of the initial and final temperatures covered a wide range.
Samples were injected by using the air plug technique (17) with control of the injection volume before and after injection.
The initial measurements with split were performed at an inlet temperature in the range of 150-275°C and a split ratio ranging from 1:10 to 1:50 (split-vent flow rate, 10-50 mL/min). A volume of 1.0-3.0 µL was injected.
The secondary cooling (17) time of the cold on-column injector was changed over the range of 0.05-0.2 min. A volume of 1.0 µL was injected.
Because each individual measurement took on average ca 40 min, the measurements were made in cycles consisting of 6 or 9 analyses; 3 chromatograms were obtained for each sample. Each measuring cycle was preceded by a system leak check, an evaluation of the chromatographic column, and a baseline stability check for any given program. For each analysis cycle for a pharmaceutical preparation, a chromatogram was obtained for one of the standard solutions. The chromatograms were recorded with baseline compensation.
The chromatograms shown in Figure 1 , a and b, were obtained for a standard solution of gliclazide with the use of 2 radically different injection techniques, split-splitless ( Figure 1a ) and cool on-column (Figure 1b) . The first chromatogram, in contrast with the other, contains several additional peaks, which could be due to the thermal decomposition of the analyte. That difference in the behavior of the analyte, depending on the injection technique used, accounts for the choice of cool on-column as a mode of injection for further examination.
The main peaks in all recorded chromatograms were characterized by repeatable retention times, shapes, and areas, but their heights were different (Table 1) . Therefore, the internal standard method was chosen for further analyses. The resolution (R; 18) of the gliclazide and phenazone peaks was calculated to control the conditions of the chromatographic separation. The criterion R ≥ 4 was used.
The results of the experiments described above are shown in Table 1 .
Selectivity and specificity of the method.-The selectivity of the method was determined by establishing the effect of potential constituents of the matrix on the gliclazide determination under specified conditions. Chromatograms of gliclazide standard and appropriate preparations were recorded to compare the individual peaks obtained (Figure 2 ). The proper peak and matrix constituents were defined on the basis of retention time and peak area. Table 1) , is repeatable and, therefore, enables easy identification.
For gliclazide the phenazone peak was the reference peak for the RRT; a criterion of ±0.5% was used.
To illustrate the levels of the matrix constituents (as percentages) in the gliclazide preparations analyzed, the relationship between the gliclazide peak area and additional peaks areas (excluding the phenazone peak area ) was examined. The GC area% calculation method was used. The results are presented in Table 2 . Accuracy and precision.-The accuracy of the method was defined in terms of analyte recovery. Therefore, a specified amount of analyte, i.e., ranging from 80 to 120% of the known concentration of the active substance in the pharmaceutical preparation, was added to samples of the preparation, which were analyzed after fortification. The mean recovery (n = 6) was 96.5%, and recoveries ranged from 91.10 to 104.03%. The standard deviation (SD) was 5.63, the relative standard deviation (RSD) was 5.85%, and the 95% confidence interval (µ) was 96.5 ± 4.17%.
The precision has been defined as the degree of consistency between the measurements repeated many times. To check the measurements for consistency, the values of the RSD and absolute SD were used, with the assumption that the result of single measurements was y = x ± 2 SD (95% confidence level).
The precision, calculated for n = 6, was as follows: y = 3.048 ± 0.0344 mg/mL (x min = 3.03 mg/mL, x max = 3.07 mg/mL, SD = 0.0172, and RSD = 0.564%).
Linearity.-The linearity was examined by using 10 solutions of different gliclazide concentrations ranging from 0.1 to 10 mg/mL. The results were analyzed by the linear regression method (Figure 3) .
Limits of detection and quantitation.-The limit of detection was based on a signal-to-noise ratio of ≥ 3 for a sample containing an appropriate amount of analyte (Figure 4a ). Similarly, the quantitation limit was determined by assuming that the peak height was ≥6 times the baseline noise (Figure 4b ). The limits of detection and quantitation were found to be 30 and 60 ng, respectively.
As a result of these examinations, the conditions of the chromatographic analyses were established.
Quantitative Analyses
The following 3 analytical methods were used: absolute calibration method (direct GC), internal standard method (GC with an internal standard), and UV spectrophotometric method (for comparison).
Quantitative GC Analyses A 1.0 µL aliquot of the appropriate solution of standard or pharmaceutical preparation was fed into the column through the cold on-column injector. The secondary cooling time of the injector was 0.1 min. The chromatograms were recorded at a constant carrier gas pressure of 100 kPa and with the following temperature program for the GC oven: from 75°C (hold for 5 min) to 240°C at 10°C/min (hold for 18 min).
The chromatograms of standard solutions were used for linearity checking and determination of retention times, response factors (RFs), and gliclazide concentrations in the pharmaceutical preparations.
The chromatograms of the examined solutions were used for the identification and determination of gliclazide.
The absolute calibration method, based on calculations with peak areas obtained by direct GC, and the internal standard method, based on calculations with peak areas or peak heights with "averaged RF" multilevel calibration, were used, together with the software capabilities.
Spectrophotometric Analyses
For spectrophotometric measurements, the standard and the pharmaceutical preparations under study were dissolved in methanol so that solutions of concentrations ranging from 5 to 20 µg/mL were obtained. The absorbance (A) was measured at λ max = 227 nm. The relationship between absorbance and concentration, A = f(c), was linear in compliance with the Lambert-Beer law. The concentration of gliclazide was calculated from absorbances recorded at λ max for relevant solutions of the standard and pharmaceutical preparations.
The results of the analyses by the 3 methods are presented in Table 3 .
Results and Discussion
The chromatograms of the standard (gliclazide) and the individual pharmaceutical preparations under study were recorded under the conditions specified above.
The results of quantitative analysis are presented in Figure 2 . There are 2 base peaks visible in chromatograms A-H. One is for gliclazide (retention time, approximately 36 min), and the second is for the internal standard phenazone (retention time, about 29 min).
The chromatograms differ from each other by the presence of additional peaks of various heights and areas, but similar retention times. It should be noted that no additional peaks are present in chromatogram A of the standard. Thus, it can be concluded that the additional peaks observed in chromatograms B-H are due either to impurities in the active substance or to auxiliary substances present in the pharmaceutical preparations.
The position of the gliclazide peaks in the Figure 2 chromatograms, defined by retention times and RRT values (Table 1) , is repeatable and enables their easy identification.
By considering the heights of the additional peaks recorded in the chromatograms, it would be possible to assess the purity of each preparation, if the peaks were identified. Because such identification was not performed in this study, it can be concluded only that the areas of the additional peaks recorded in chromatograms C, D, E, and G are larger than those of the additional peaks in chromatograms B, F, and H, and that these results suggest various impurity levels ( Table 2) .
Regardless of the origin of the additional peaks, the aim of this study, i.e., to develop a method for the determination of the active substance without matrix constituents, appears to be achieved; because the gliclazide peak recorded under established conditions differs significantly in retention time from the additional peaks, the active substance can be determined independently.
Although the peaks obtained under the established conditions are not symmetrical, the results presented in Table 3 are repeatable, as shown by the statistical evaluation. The preliminary validation procedure confirmed the credibility of the developed method, which guarantees that reliable analytical results can be obtained.
The relationship between peak area and concentration indicates a wide linearity range from 0.1 to 10 mg/mL. The equation describing the calibration line contains a small value of parameter b (Figure 3) .
The developed method is also characterized by high gliclazide recoveries averaging 96.5% and low detection and quantitation limits of 30 and 60 ng, respectively.
Determination of the gliclazide content of tablets by the GC direct method produced divergences between declared content and amount found that were greater than those obtained by UV spectrophotometry or by the GC with internal standard method (Table 3) . Much better results were obtained when the calculations for the GC with internal standard method were based on peak area rather than on peak height.
Under the established conditions of the GC analysis with the use of the internal standard and calculations based on peak areas, the values for relative error (E rel ), RSD, and 95% confidence interval were lower than those obtained by direct GC or by the GC with internal standard method with calculations based on peak heights (Table 3) . Thus, it appears that the developed method-the GC with internal standard method with calculations based on peak area-produces the best results and should be recommended for the determination of gliclazide.
The results for gliclazide determination obtained by UV spectrophotometry (Table 3) are consistent with those obtained by the GC with internal standard method with calculations based on peak area. The former are higher for preparations G and H only, probably because of the effect of matrix constituents on direct UV measurements. However, this explanation was not confirmed by the results for preparations B and F, both of which have additional chromatographic peaks that are similar to those of G and H. Therefore, it can only be concluded that preparations G and H also contain other matrix constituents that increase the UV absorbance but are undetectable in chromatograms.
Conclusions
Conditions were established for the identification and determination of gliclazide in pharmaceutical preparations by capillary GC. The most accurate and repeatable results were obtained by the GC with internal standard method with calculations based on peak area, regardless of the origin of the drugs. These results indicate the high selectivity and precision of the proposed method. Any influence of matrix constituents was eliminated under the specified conditions.
Results confirmed that the developed method can also be used to assess drug purity, provided that the additional chromatographic peaks are identified. These peaks might indicate manufacturing impurities or decomposition products of the active substance.
The developed method is characterized by high recovery (96.5%) and low limits of detection and quantitation (30 and 60 ng, respectively). Furthermore, the method is linear within a wide concentration range (0.1-10.0 mg/mL). The results of the quantitative analyses as well as the statistical data clearly demonstrate that the developed method is precise.
The cool on-column injection mode contributed greatly to the satisfactory analytical results.
